Early data from a Phase II clinical trial show a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.
A new study has found that introducing efgartigimod alfa as a treatment option in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (IG) or intravenous IG would result in substantially increased spending in the treatment of CIPD.
A study has found that for patients with certain types of advanced lung or skin cancer, administration of a SARS-CoV-2 mRNA vaccine within 100 days of starting immune checkpoint inhibitors is associated with increased overall survival.
A retrospective cohort study has found respiratory syncytial virus infections are associated with substantial morbidity among patients with systemic autoimmune rheumatic diseases, with more than half of infected individuals requiring hospitalization.
A new study has found people have an increased risk of major cardiovascular events following viral infections such as SARS-CoV-2, influenza, HIV, hepatitis C and varicella zoster virus.
A recent study shows the use of hormone therapy in postmenopausal women was associated with a significantly higher incidence and risk of autoimmune diseases.
The HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older who are prescribed HYQVIA.
Grifols Therapeutics has initiated a voluntary withdrawal of four lots of Gamunex-C 10%.
FDA has accepted a supplemental new drug application for leniolisib to treat activated phosphoinositide 3-kinase delta syndrome, or APDS, in children aged 4 to 11 years.
New research has found that patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine.
The U.S. Food and Drug Administration has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
A small study of medical records unexpectedly found that 12 percent of chronic pain patients who were treated with spinal cord stimulation or an implanted pain medicine pump had a white blood cell condition called eosinophilia.